Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 24;23(19):11271.
doi: 10.3390/ijms231911271.

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment

Iason Psilopatis  1   2 , Stefania Kokkali  2   3 , Kostas Palamaris  2 , Antonia Digklia  4 , Kleio Vrettou  2 , Stamatios Theocharis  2
Affiliations
Review

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment

Iason Psilopatis et al. Int J Mol Sci. .

Abstract

Sarcomas are malignant tumors of mesenchymal origin that can occur at any age. The rarity of these tumors in combination with the vast number of histological subtypes render the study of sarcomas challenging. Organoids represent complex three-dimensional cell culture systems, deriving from stem cells and preserving the capacity to differentiate into the cell types of their tissue of origin. The aim of the present review is to study the current status of patient-derived organoids, as well as their potential to model tumorigenesis and perform drug screenings for sarcomas. In order to identify relevant studies, a literature review was conducted and we were able to identify 16 studies published between 2019 and 2022. The current manuscript represents the first comprehensive review of the literature focusing on the use of organoids for disease modelling and drug sensitivity testing in diverse sarcoma subtypes.

Keywords: organoids; sarcoma; three-dimensional cell culture.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient-derived sarcoma organoids for disease modeling and drug sensitivity testing. Created with BioRender.com (accessed on 26 July 2022).
Figure 2
Figure 2
PRISMA flow diagram visually summarizing the screening process.
See this image and copyright information in PMC

References

    1. Hui J.Y. Epidemiology and Etiology of Sarcomas. Surg. Clin. N. Am. 2016;96:901–914. doi: 10.1016/j.suc.2016.05.005. - DOI - PubMed
    1. Skubitz K.M., D’Adamo D.R. Sarcoma. Mayo. Clin. Proc. 2007;82:1409–1432. doi: 10.4065/82.11.1409. - DOI - PubMed
    1. Lupo P.J., Spector L.G., O’Brien S., Schiffman J.D., Hettmer S. Epidemiology of Bone and Soft Tissue Sarcomas. In: Arnd C.A.S., editor. Sarcomas of Bone and Soft Tissues in Children and Adolescents. Pediatric Oncology; Springer; Cham, Switzerland: 2020.
    1. American Cancer Society. Key Statistics for Soft Tissue Sarcomas. [(accessed on 17 June 2022)]. Available online: https://www.cancer.org/cancer/soft-tissue-sarcoma/about/key-statistics.html.
    1. American Cancer Society. Key Statistics about Bone Cancer. [(accessed on 17 June 2022)]. Available online: https://www.cancer.org/cancer/bone-cancer/about/key-statistics.html.

LinkOut - more resources